PMGC Holdings (ELAB) EBIT Margin (2022 - 2026)
PMGC Holdings (ELAB) posted EBIT Margin of 488.74% for Q1 2026, up 39.77% sequentially from 811.41% in Q4 2025, and down 56870.0% YoY from N/an in Q1 2025.
PMGC Holdings (ELAB) EBIT Margin (2022 - 2026) Analysis & Trends
PMGC Holdings has reported EBIT Margin for 5 years, with the latest figure at 488.74% in Q1 2026.
- Quarterly EBIT Margin fell 56870.0% year-over-year to 488.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 628.88% (down 62583.0% YoY) and the FY2025 annual result came in at 1166.27%, down 109062.0% from the prior year.
- EBIT Margin climbed to 488.74% in Q1 2026 per ELAB's latest filing, from 811.41% in the prior quarter.
- Over five years, EBIT Margin peaked at 298.09% in Q4 2024 and troughed at 811.41% in Q4 2025.
- A 5-year average of 277.21% and a median of 205.29% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin surged 45282 bps in 2024, then plunged 110951 bps in 2025.
- Over 5 years, EBIT Margin stood at 177.96% in 2022, then climbed by 13 bps to 154.73% in 2023, then jumped by 293 bps to 298.09% in 2024, then plunged by 372 bps to 811.41% in 2025, then jumped by 40 bps to 488.74% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 488.74%, 811.41%, and 768.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | PMGC Holdings | 30.58 Mn | 11.78 Mn | 385,691.00 | -292.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -488.74% |
| Dec 31, 2025 | -811.41% |
| Sep 30, 2025 | -768.99% |
| Mar 31, 2025 | 79.96% |
| Dec 31, 2024 | 298.09% |
| Sep 30, 2024 | -174.38% |
| Jun 30, 2024 | -232.62% |
| Mar 31, 2024 | -273.93% |
| Dec 31, 2023 | -154.73% |
| Sep 30, 2023 | -141.63% |
| Jun 30, 2023 | -332.77% |
| Mar 31, 2023 | -592.63% |
| Dec 31, 2022 | -177.96% |
| Sep 30, 2022 | -109.19% |